Vamecq J, Latruffe N: Medical significance of peroxisome proliferator-activated receptors. Lancet. 1999, 354: 141-148. 10.1016/S0140-6736(98)10364-1.
Article
CAS
PubMed
Google Scholar
Tenenbaum A, Fisman EZ, Motro M: Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). Cardiovasc Diabetol. 2003, 2: 4-10.1186/1475-2840-2-4.
Article
PubMed Central
PubMed
Google Scholar
Berger JP, Akiyama TE, Meinke PT: PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol Sci. 2005, 26: 244-251. 10.1016/j.tips.2005.03.003.
Article
CAS
PubMed
Google Scholar
Kota BP, Huang TH, Roufogalis BD: An overview on biological mechanisms of PPARs. Pharmacol Res. 2005, 51: 85-94. 10.1016/j.phrs.2004.07.012.
Article
CAS
PubMed
Google Scholar
Fruchart JC, Staels B, Duriez P: The role of fibric acids in atherosclerosis. Curr Atheroscler Rep. 2001, 3: 83-92.
Article
CAS
PubMed
Google Scholar
Desvergne B, Michalik L, Wahli W: Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol. 2004, 18: 1321-1332. 10.1210/me.2004-0088.
Article
CAS
PubMed
Google Scholar
Argmann CA, Cock TA, Auwerx J: Peroxisome proliferator-activated receptor gamma: the more the merrier?. Eur J Clin Invest. 2005, 35: 82-92. 10.1111/j.1365-2362.2005.01456.x.
Article
CAS
PubMed
Google Scholar
Auwerx J: PPARgamma, the ultimate thrifty gene. Diabetologia. 1999, 42: 1033-1049. 10.1007/s001250051268.
Article
CAS
PubMed
Google Scholar
Lazar MA: PPAR gamma, 10 years later. Biochimie. 2005, 87: 9-13. 10.1016/j.biochi.2004.10.021.
Article
CAS
PubMed
Google Scholar
Fredenrich A, Grimaldi PA: PPAR delta: an uncompletely known nuclear receptor. Diabetes Metab. 2005, 31: 23-27.
Article
CAS
PubMed
Google Scholar
Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, Peters JM: The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell Signal. 2005, Aug 15.
Staels B, Fruchart JC: Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005, 54: 2460-2470.
Article
CAS
PubMed
Google Scholar
Israelian-Konaraki Z, Reaven PD: Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiology. 2005, 103: 1-9. 10.1159/000081845.
Article
PubMed
Google Scholar
Forcheron F, Cachefo A, Thevenon S, Pinteur C, Beylot M: Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes. 2002, 51: 3486-3491.
Article
CAS
PubMed
Google Scholar
Chinetti G, Lestavel S, Fruchart JC, Clavey V, Staels B: Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ Res. 2003, 92: 212-217. 10.1161/01.RES.0000053386.46813.E9.
Article
CAS
PubMed
Google Scholar
Despres JP, Lemieux I, Robins SJ: Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Drugs. 2004, 64: 2177-2198.
Article
CAS
PubMed
Google Scholar
Giannini S, Serio M, Galli A: Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest. 2004, 27: 982-991.
Article
CAS
PubMed
Google Scholar
Staels B: PPARgamma and atherosclerosis. Curr Med Res Opin. 2005, 21 (Suppl 1): S13-20. 10.1185/030079905X36440.
Article
CAS
PubMed
Google Scholar
Luquet S, Gaudel C, Holst D, Lopez-Soriano J, Jehl-Pietri C, Fredenrich A, Grimaldi PA: Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim Biophys Acta. 2005, 1740: 313-317.
Article
CAS
PubMed
Google Scholar
Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, Varghese Z: PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol. 2003, 14: 593-600. 10.1097/01.ASN.0000050414.52908.DA.
Article
CAS
PubMed
Google Scholar
Goldfarb B: PPAR benefits beyond glucose control. Cardiovascular effects may be even greater with next generation. DOC News. 2005, 2: 14.
Google Scholar
Bays H, Stein EA: Pharmacotherapy for dyslipidaemia – current therapies and future agents. Expert Opin Pharmacother. 2003, 4: 1901-1938.
Article
CAS
PubMed
Google Scholar
Bailey CJ: New pharmacologic agents for diabetes. Curr Diab Rep. 2001, 1: 119-126.
Article
CAS
PubMed
Google Scholar
Pegorier JP: [PPAR receptors and insulin sensitivity: new agonists in development]. Ann Endocrinol (Paris). 2005, 66: 1S10-17.
Article
CAS
Google Scholar
Darves B: Muraglitazar may help lower glucose and cholesterol levels in type 2 diabetes. Medscape Medical News, ADA 65th Annual Scientific Sessions: Abstracts 967, 14-OR. 2005, [http://www.medscape.com/viewarticle/506546]
Google Scholar
Peters JM, Aoyama T, Burns AM, Gonzalez FJ: Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice. Biochim Biophys Acta. 2003, 1632: 80-89.
Article
CAS
PubMed
Google Scholar
Cabrero A, Alegret M, Sanchez RM, Adzet T, Laguna JC, Vazquez M: Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes. Diabetes . 2001, 50: 1883-1890.
Article
CAS
PubMed
Google Scholar
Poirier H, Niot I, Monnot MC, Braissant O, Meunier-Durmort C, Costet P, Pineau T, Wahli W, Willson TM, Besnard P: Differential involvement of peroxisome-proliferator-activated receptors alpha and delta in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine. Biochem J. 2001, 355: 481-488. 10.1042/0264-6021:3550481.
Article
PubMed Central
CAS
PubMed
Google Scholar
Vazquez M, Roglans N, Cabrero A, Rodriguez C, Adzet T, Alegret M, Sanchez RM, Laguna JC: Bezafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal beta-oxidation in rat white adipose tissue. Mol Cell Biochem. 2001, 216: 71-78. 10.1023/A:1011060615234.
Article
CAS
PubMed
Google Scholar
Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W: Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997, 11: 779-791. 10.1210/me.11.6.779.
Article
CAS
PubMed
Google Scholar
Moya-Camarena SY, Van den Heuvel JP, Belury MA: Conjugated linoleic acid activates peroxisome proliferator-activated receptor alpha and beta subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats. Biochim Biophys Acta. 1999, 1436: 331-342.
Article
CAS
PubMed
Google Scholar
Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000, 43: 527-550. 10.1021/jm990554g.
Article
CAS
PubMed
Google Scholar
Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med. 2002, 53: 409-435. 10.1146/annurev.med.53.082901.104018.
Article
CAS
PubMed
Google Scholar
Meade T, Zuhrie R, Cook C, Cooper J: Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ. 2002, 325: 1139-10.1136/bmj.325.7373.1139.
Article
PubMed Central
CAS
PubMed
Google Scholar
Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A: Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol. 1997, 8: 1125-1129. 10.1016/S0002-9149(97)00626-7.
Article
Google Scholar
Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD: Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998, 21: 641-648.
Article
CAS
PubMed
Google Scholar
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000, 102: 21-27.
Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005, 165: 1154-1160. 10.1001/archinte.165.10.1154.
Article
CAS
PubMed
Google Scholar
Taniguchi A, Fukushima M, Sakai M, Tokuyama K, Nagata I, Fukunaga A, Kishimoto H, Doi K, Yamashita Y, Matsuura T, Kitatani N, Okumura T, Nagasaka S, Nakaishi S, Nakai Y: Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism. 2001, 50: 477-480. 10.1053/meta.2001.21028.
Article
CAS
PubMed
Google Scholar
Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH: Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med. 2002, 112: 275-280. 10.1016/S0002-9343(01)01123-8.
Article
CAS
PubMed
Google Scholar
Kim JI, Tsujino T, Fujioka Y, Saito K, Yokoyama M: Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens Res. 2003, 26: 307-313. 10.1291/hypres.26.307.
Article
CAS
PubMed
Google Scholar
Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S: Peroxisome proliferator-activated receptors ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004, 109: 2197-2202. 10.1161/01.CIR.0000126824.12785.B6.
Article
CAS
PubMed
Google Scholar
Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, Leor J, Boyko V, Schwammenthal E, Behar S: Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J. 2005, 26: 2032-2038.
Article
CAS
PubMed
Google Scholar
Comments
View archived comments (1)